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ABSTRACT 
Background and Objectives: The incidence of fungal infections in immunocompromised patients, especially by Candida 
species, has increased in recent years. This study was designed to identify Candida species and determine antifungal 
susceptibility patterns of 595 yeast strains isolated from various clinical specimens.
Material and Methods: Identification of the isolates were determined by the API 20 C AUX kit and antifungal susceptibilities 
of the species to fluconazole, amphotericin B, ketoconazole, itraconazole, voriconazole, and caspofungin  were determined 
by the agar-based E-test method. 
Results: Candida albicans (48%) was the most frequently isolated species, followed by Candida kruzei (16.1%), Candida 
glabrata (13.5%), Candida kefyr (7.4%), Candida parapsilosis (4.8%), Candida tropicalis (1.7%) and other species (8.5%). 
Resistance varies depending on the species and the respective antifungal agents. Comparing the MIC90 for all the strains, the 
lower MIC90 was observed for caspofungin (0.5 µg/ml). The MIC90 for all Candida species were 64 µg/ml for fluconazole, 
0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.
Conclusions: Species definition and determination of antifungal susceptibility patterns are advised for the proper management 
and treatment of patients at risk for systemic candidiasis. Resistance to antifungal agents is an alarming sign for the emerging 
common nosocomial fungal infections.
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INTRODUCTION
Systemic  candidiasis  (SC)  is  the  most  common 
invasive fungal infection as the nosocomial infection 
in  patients  undergoing  major  surgeries  during 
prolonged neutropenia, transplantation and extended 
hospital stays of days to weeks, (1). This infection 
is  potentially  a  life-threatening  complication  in 
immunocompromised  patients. The  introduction  of 
novel antineoplastic agents, antifungals, antibacterial 
and antivirals over the past 10 years has led to a shift in 
fungal epidemiology (2, 3) and fever without specific 
signs and symptoms of localized fungal infection is 
the  most  common  clinical  presentation.  Intensive 
and long-term use of antifungals leads to a decline 
in sensitivity and resistance development of Candida 
strains (4). Antifungal resistance surveillance serves 
as a major strategy for prophylaxis, empirical therapy, 
and treatment of SC. For the management of patients 
suffering from SC, determination of the changes in 
the  distribution  of  Candida  species  and  respective 
sensitivity pattern to antifungal agents are important. 
Antifungal prophylaxis is warranted in patients with 
developing risk of SC. As definitive early diagnosis 
is difficult, empiric therapy of antifungal agents has 
become a standard of practice in immune-suppressed 
patients like neutropenic patients who had received 
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broad  spectrum  antibacterial  therapy  but  remain 
persistently  febrile.  The  antifungal  susceptibility 
testing of pathogenic fungi can manage the selection 
of adequate therapy and also provide an estimate of 
antifungal  efficacy.  Monitoring  of  drug  resistance 
development  can  predict  therapeutic  outcome  and 
therapeutic potential of untested compounds (5-7). 
The  purpose  of  this  study  was  to  determine 
the  distribution  of  Candida  species  and  in  vitro 
susceptibilities  of    antifungal  agents  against  the 
Candida  isolated  from  the  patients  referred  to  a 
mycology center in southern Iran using E-test for the 
best management and treatment of those at risk for SC .
MATERIALS AND METHODS
This study was designed in mycology department, 
Clinical  Microbiology  Research  Center,  Shiraz 
University of Medical Sciences, southern Iran from 
October  2005  to  October  2010.  Clinical  samples 
including  mouth,  blood,  abdominal  tap,  urine, 
sputum, esophageal, oropharyngeal, vagina, biopsy 
and broncho alveolar lavage of patients were cultured 
on saboaroud dextrose agar (Merck, Germany) and 
incubated  at  24°C  for  10  days. All  Candida  spp. 
isolated were cultured on potato dextrose agar (OXOID 
LTD,  Basingstoke,  Hampshire,  England)  twice  for 
48h  at  35°C  for  the  purity  inspected.  For  species 
typing of the isolates, germ tube and chlamydospore 
production tests were performed. The carbohydrate 
assimilation patterns of all the isolates were studied 
using the API 20 C AUX system according to the 
manufacturer’s  procedure  (Biomerieux,  France). 
Candida  (C)  dubliniensis  sp.  was  recognized  by 
molecular assay from Candida albicans (8) because 
these species have the same pattern for carbohydrate 
assimilation. Candida parapsilosis ATCC 22019 and 
Candida krusei ATCC 6258 (9) were quality controls 
and tested each day for all antifungal agents.
 Susceptibility test for the isolates was performed 
by  the  agar-based  E-test  method  (Biomeriux, 
Sweden) with RPMI 1640, 8.4 gram per litter (RPMI; 
Sigma Chemical Co., St. Louis, Mo.), 2% glucose 
and1.5% agar which buffered to PH 7.0 with 0.165 
M morpholinepropanesulfonic acid buffer (Sigma, St. 
Louis, Mo.), poured in 90-mm-diameter plates. The 
plates were inoculated by dipping a sterile swab into 
the inoculum suspension adjusted to the turbidity of 
a 0.5 McFarland standard (106 cells/ml) and streaking 
it across the surface of the agar in four directions. 
The  plates  were  dried  at  ambient  temperature  for 
15  minutes  before  applying  the  E-test  strips.  The 
minimum inhibition concentrations (MIC) endpoints 
were determined after 24 and 48 h of incubation at 
35°C.  The MIC was read for amphotericin B, as the 
drug concentration that zone determined the point of 
complete  inhibition  (100%),  and  for  ketoconazole; 
itraconazole,  voriconazole  and  caspofungin  the 
significant inhibition decreased 80% of the growth. 
The  resistance  breakpoints  for  antifungals  are 
amphotericin B > 1.0; fluconazole ≥ 64; itraconazole 
≥ 1.0; voriconazole ≥ 8.0; ketoconazole ≥ 4.0; and 
caspofungin ≥ 2.0 micrograms per milliliter (10-15). 
MIC50 and MIC90 (the MIC at which 50% and 90% 
of the isolates are inhibited) were also calculated. 
Data were entered into SPSS version 16 and were 
subsequently analyzed using descriptive statistics and 
cross tabulation. 
RESULTS
Totally, 595 Candida spp. were isolated from the 
Species No. of isolates % of isolates
Candida albicans 285 48%
Candida krusei 96 16.1%
Candida glabrata 80 13.5%
Candida kefyr 44 7.4%
Candida parapsilosis 29 4.8%
Candida tropicalis 10 1.7%
Others* 51 8.5%
Total 595 100
Table 1. Distributions of Candida species isolates from patients 2005-2009. 
*Others include C. dublinensis 9, C.apicola 8, C. famata 4, C. zeylanoides 6, Cryptococcus neoformans 9, Trichosporon 
beigelii. 8, Saccharomyces cervicea 7.185 SUSCEPTIBILITy  TEST Of Candida speCies 
Species (no. isolates) Antifungal agent       Range 50% 90% Number of  Resistance (%)
C.albicans (285)
Fluconazole
Amphotericin
Ketoconazole
Itraconazole
Voriconazole
Caspofungin
1.00-64.0
0.032-1.00
0.002-16.00
0.016-4.00
0.025- 0.003-16.00
1.00
4.000
 0.032
 0.064
 0.190
  0.064
       0.025
16.00
0.500
4.00
2.00
4.00
0.075
30 (10.5%)
20 (7%)
27 (9.4%)
96 (33.7%)
17 (6%)
5 (1.8%)
C. krusei (96)
Fluconazole
Amphotericin
Ketoconazole
Itraconazole
Voriconazole
Caspofungin
4.00-64.00
0.064-1.00
0.380-32.00
0.500-16.00
0.100-32.00
0.015-0.5
8.00
0.125
1.500
0.5.00
0.500
0.24
128.00
0.250
4.00
4.00
2.00
0.500
64 (66.6%)
3 (3.1%)
10 (10.4%)
83 (86.5%)
19 (19.8%)
4 (4.2%)
C. glabrata (80)
Fluconazole
Amphotericin
Ketoconazole
Itraconazole
Voriconazole
Caspofungin
0.75-256
0.013-1
0.013-12
0.500-16.0
0.012-8.00
0.03-4.00
64.00
0.190
1.500
2.00
0.750
0.06
128.0
0.500
6.00
16.00
3.00
0.12
48 (60%)
2 (2.5%)
12 (15%)
68 (85%)
8 (10%)
3 (3.7%)
C. Kefyr (44)
C. parapsilosis(29)
Fluconazole
Amphotericin
Ketoconazole
Itraconazole
Voriconazole
Caspofungin
Fluconazole
Amphotericin
Ketoconazole
Itraconazole
Voriconazole
Caspofungin
0.038-128.0
0.016-1.00
0.012-0.190
0.002-1.00
0.008-16.00
0.03-1
2.00-64.00
0.023-0.500
0.016-0.064
0.023-0.500
0.006-0.047
0.03-2
1.00
0.190
0.032
0.047
0.023
0.064
1.00
0.250
0.023
0.125
0.016
0.25
8.000
0.750
0.047
0.500
0.064
0.125
4.00
0.500
0.047
0.250
0.032
1.00
20 (45.5%)
2 (4.5%)
1 (2.3%)
5 (11.4%)
1 (2.3%)
1 (2.3%)
2 (6.9%)
1 (3.5%)
1 (3.5%)
1 (3.5%)
0.00
0.00
Table 2. Distributions of MIC (µg/ml) by E-test methoda.                                                                                                                                         
Resistance is defined as the following MIC in micrograms per milliliter: Flu ≥ 64; AMB > 1.0; Keto ≥ 4.0; Itra ≥ 1.0; Vori ≥ 
4.0; and Caspofungin ≥ 2.0.
patients. The most sites of the isolated (70%) were 
mouth and lung (sputum and bronchoalveolar lavage), 
but  Candida  species  were  also  isolated  from  the 
blood, cerebro spinal fluid, sinus biopsy, eyes, pleural 
and abdominal tap. The most species isolated from 
the patients was C. albicans followed by C. krusei, C. 
glabrata, C. kefyr, and C. parapsilosis (Table 1). 
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sensitive to caspofungin, voriconazole, amphotericine 
B,  ketoconazole,  and  fluconazole  with  98.2%, 
94%,  93%,  90.6%,  and  89.5%,  respectively.  Of 
the 96 C. krusei strains, 32 (33.4%) were sensitive 
to fluconazole, 93 (96.9%) to amphotericine B, 86 
(89.6%) to ketoconazole, 77 (80.2%) to voriconazole 
and 92 (95.8%) to caspofungin. Among the 80 C. 
glabrata, the third isolated species, 32 (40%) were 
found to be sensitive to fluconazole, 78 (97.5%) to 
amphotericine B, 68 (85%) to ketoconazole, 72 (90%) 
to  voriconazole  and  77  (96.3%)  to  caspofungin.   
Candida  kefyr  species  had  the  least  sensitivity  to   
fluconazole 24 (54.5%), and high sensitivity (> 85%) to 
the other antifungals. Candida Parapsilopsis species 
showed  high sensitivity rate to all antifungal agents. 
The lowest sensitivity was seen to itraconazole, C. 
albicans 189 (66.3%), C. glabrata 12 (15%), and C. 
krusei 13 (13.5%). Table 2 presents the antifungal 
susceptibility testing of Candida isolates to antifungal 
agents by E-test. 
Comparing  the  MIC90  of  species,  the  lowest 
MIC90 was observed for caspofungin (0.5 µg/ml). 
The MIC90 for all Candida species were 64 µg/ml 
for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/
ml for ketoconazole, 4 µg/ml for itraconazole, and 2 
µg/ml for voriconazole.
DISCUSSION
In  the  present  study,  the  agar-based  E-test  was 
used and performed well for the testing of antifungal 
agents as there are reports about the usefulness of this 
method and agreement between the E-test and the 
broth micro-dilution MIC for Candida species and 
different types of antifungal agents (16, 17). 
In this study, we isolated 595 strains from various 
clinical samples with higher rate of C. albicans (48%), 
followed by C. glabrata (13.5%) and C. Parapsilosis 
(4.8%) (Table 1). The distributions of the species are 
different in various regions and studies, like 50% C. 
albicans, 24.7% C. glabrata, and 1% C. parapsilosis 
in other studies (18, 19). These observations establish 
the  great  importance  of  non  -albicans  Candida  as 
a pathogen in clinical samples. It is important that 
increase in non-albicans species in SC with intensive 
and long-term use of antifungals leads to higher level 
of  resistance  of  Candida  strains  to  the  antifungal 
drugs (20-22). A remarkable point in our study is that 
the most commonly isolated species was C. albicans 
in the clinical samples  followed by C. krusei and 
C. glabrata which can pose a serious threat due to   
resistance to the routine antifungal agents. 
Amphotericin B deoxycholate was the first systemic 
antifungal agent for the treatment of invasive fungal 
infections and has been the drug of choice (23, 24), 
however, due to nephrotoxicity in up to 80% of the 
patients, use of amphotericin B has been limited (25). 
Specific breakpoint for amphotericin B has not been 
proposed because it can positively affect the immune 
system  and  stimulates  the  body  defenses  against 
fungal infections (26, 27); therefore, the correlation 
between  in  vitro  susceptibility pattern  and  in  vivo 
responses in patients is not predictable. Resistance 
to amphotericin B as a routine antifungal agent and 
valid in our hospital for SC, varies in different studies. 
All  Candida  isolates  in  Tseng  et  al.  2005,  were 
susceptible to amphotericin (17) but in our study 7% 
of C. albicans with MIC90, 0.500 µg/ml, 3.1% of C. 
krusei (MIC90 0.250 µg/ml), and 2.5% of C. glabrata 
(MIC90 0.500 µg/ml) were resistant to it.
Development  of  the  triazoles  in  the  1990s 
provided alternative options for treating SC. Long-
term fluconazole and itraconazole prophylaxis was 
associated with reduction in susceptibility to these 
agents. Susceptibility of C. albicans to fluconazole 
in  this  study  was  89.5%  (at  MIC  ≤  16  μg/mL), 
comparable with the susceptibility rates reported in 
other studies (80.9%, 87%, 79% and 87.5%) (17, 28- 
30). The resistant rate of C. albicans to itraconazole 
in this study was 33.7%, and MIC90% for it was 
presented ≤ 6 µg/ml.  Different rates of resistance to 
fluconazole and itraconazole were detected in Candida 
strains especially non albicans strain (14, 18). From 
the standpoint of antifungal resistance, C. glabrata 
and C. krusei are clearly the Candida species with the 
greatest potential to acquire resistance to fluconazole 
and other azoles (14, 15). Of the 96 C. krusei strains, 
83 (86.3%) were resistant to itraconazole, 64 (66.6%) 
to fluconazole, 19 (19.8%) to voriconazole, 4 (4.2%) 
to  caspofungin,  and  3  (3.1%)  to  amphotericine  B. 
Also, the MIC of C. glabrata was higher than that 
for all other species of Candida to triazoles agents 
(Table 2). 
Blood  stream  infection  due  to  C.  kefyr  is 
uncommon,  but  there  has  been  some  reports  in 
immunocompromised patients (31) and resistance to 
antifungals in the literature (4, 20).  In the present 
study,  7.4%  of  Candida  isolates  were    C.  kefyr, 
of which 45.5%  were resistant to fluconazole but 
sensitive to the other antifungals.   187 SUSCEPTIBILITy  TEST Of Candida speCies 
There  were  many  species  which  resisted  two  or 
three azole antifungal agents and with higher MIC 
for other azole antifungal agents. This shows that the 
resistance to one azole can lead to resistance to other 
azoles, as reported in other studies (14, 15) and thus, 
is a caution for use of this agent in clinical practice.
Caspofungin  is  the  first  echinocandin,  approved 
in 2002 with the mechanism of inhibiting the 1, 3-β 
d-glucan as an integral part of the fungal cell wall. 
In the present study, caspofungin was the most active 
compound  inhibiting  90%  of  C.  albicans  isolates 
at 0.075 µg/ml, C. krusei in 0.5 µg/ml, C. glabrata 
in  0.12  µg/ml;  C.  Kefyr  in  0.125  µg/ml;  and  C. 
parapsilosis in 1.0 µg/ml. Some species such as C. 
parapsilosis and C. guilliermondii have a relatively 
higher echinocandin MIC (32).
There  are  many  view  points  on  the  use  of  new 
antifungal  agents.  Such  agents  are  very  effective 
but in many countries, especially in the developing 
ones,  they  are  very  expensive  or  not  available  to 
the respective patients. Therefore, we need to know 
the antifungal susceptibility rates in each region for 
the  available agents  in  order  to  better  manage  the 
patients.  
The  successful  treatment  of  SC  depends  on  the 
early  identification  of  the  species  and  sensitivity 
patterns  to  antifungal  agents.  The  high  growing 
rate  of  non  albicans  Candida  resistant  to  azole 
confirms  the  importance  of  monitoring  changes  in 
the distribution of pathogenic Candida species. The 
sensitivity pattern of Candida species as revealed in 
this study shows that amphotericin B, voriconazole, 
and  caspofungin  with  the  lowest  MIC  seem  to  be 
suitable drugs for empirical therapy and fluconazole 
and itraconazole are not suitable because of their high 
MIC and Candida species resistance to them. 
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